Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA)

被引：1
|
作者：
Logothetis, C. J.
Wen, S.
Molina, A.
Chieffo, N.
Smith, L. A.
Troncoso, P.
Efstathiou, E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cougar Biotechnol, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5017
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
    Joshi, Amit
    Shrirangwar, Sameer
    Noronha, Vanita
    Sable, Nilesh
    Agarwal, Archi
    Popat, Palak
    Bhattacharjee, Atanu
    Prabhash, Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2020, 9 (01) : 23 - 26
  • [43] Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
    George, Daniel J.
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru
    Berry, William R.
    Healy, Patrick
    Winters, Carolyn
    Riggan, Colleen
    Anand, Monika
    Kephart, Julie
    Milowsky, Matthew I.
    Fleming, Mark T.
    Balaji, K. C.
    Zhang, Tian
    Bitting, Rhonda L.
    Harrison, Michael Roger
    McNamara, Megan Ann
    Freedman, Jennifer A.
    Halabi, Susan
    Armstrong, Andrew J.
    Bruner, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [44] Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Tsikkinis, A.
    Wen, S.
    Tapia, E. Li Ning
    Hoang, A.
    Aparicio, A.
    Tu, S-M.
    Rangel, G.
    Troncoso, P.
    Corn, P.
    Araujo, J.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)
    Espana Fernandez, S.
    Piulats, J. M.
    Sala, N.
    Velarde, J. M.
    Ferrandiz, U.
    Etxaniz Ulazia, O.
    Heras Lopez, L.
    Barretina Ginesta, M. P.
    Garcia del Muro, X.
    Font, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients
    Wissing, M. D.
    Coenen, J. L. L. M.
    Van den Berg, P.
    Van Oort, I. M.
    De Wit, R.
    Bergman, A. M.
    Westgeest, H. M.
    Hamberg, P.
    Los, M.
    Gelderblom, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S698 - S698
  • [47] SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Huang, Ahong
    Wang, Li
    Baser, Onur
    George, Daniel
    JOURNAL OF UROLOGY, 2019, 201 (04): : E242 - E243
  • [48] Frequency of liver test increases on abiraterone acetate in men with castrate-resistant prostate cancer (CRPC): Natural history, management, and outcome.
    Colomba, Emeline
    Marret, Gregoire
    Baciarello, Giulia
    Massard, Christophe
    Loriot, Yohann
    Albiges, Laurence
    Carton, Edith
    Alexandre, Jerome
    Huillard, Olivier
    Culine, Stephane
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC)
    Gulley, James L.
    Arlen, Philip M.
    Madan, Ravi
    Lechleider, Robert L.
    Dahut, William L.
    Lowy, Israel
    Schlom, Jeffrey
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3381S - 3381S
  • [50] Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate
    Kessler, E. R.
    Gao, D.
    Flaig, T. W.
    Breaker, K.
    Wold, M.
    Wacker, M.
    Lam, E. T.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 668 - 668
12345